Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This trial is linked to a largescale observational study determining the efficacy of
sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The
observational study will identify a cohort of patients who have not responded to first-line
antiviral therapy (sofosbuvir plus daclatasvir) and the optimal treatment for these patients
is unclear. This trial will address this issue by comparing two second-line treatment
regimens to determine the preferred treatment option.
Phase:
N/A
Details
Lead Sponsor:
Queen Mary University of London
Collaborators:
Aga Khan University Bristol University Dow University, Pakistan University of Oxford